ArticleJournal of the American Heart Association2024
Proteomic Associations of Adverse Outcomes in Human Heart Failure.
Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Diagnostic and Prognostic Potential of Tetranectin in Heart Failure and Cardiovascular Disease: A Systematic Review.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Dietary Sodium-Regulated Plasma SVEP1 and Inverse Salt Sensitivity.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Exercise-Induced Plasma Surfactant Protein B Response in Advanced Heart Failure: Relation to Exercise Limitation, Resting Invasive Hemodynamics, and Clinical Outcomes.International journal of molecular sciences · 2026Article
- Challenges and future directions for Mendelian randomization.Nature genetics · 2026Review
- Plasma Proteins Associated With Psychosocial Factors and Heart Disease: The Jackson Heart Study.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- A novel plasma proteomic signature predicts long-term incident heart failure risk among persons living with HIV.medRxiv : the preprint server for health sciences · 2026Article
- Unsupervised Learning Based on Proteomic Signatures Identifies Distinct Subgroups of Heart Failure With Mildly Reduced Ejection Fraction.Journal of cardiovascular translational research · 2025Article
- Molecular Phenogroups in Heart Failure: Large-Scale Proteomics in a Population-Based Cohort.Circulation. Genomic and precision medicine · 2025Article
- Clinical Insights from Proteomics in Heart Failure.Current heart failure reports · 2025Review
- Large-scale multi-omics identifies drug targets for heart failure with reduced and preserved ejection fraction.Nature cardiovascular research · 2025Article
- Potential of plasma biomarkers for heart failure prediction, management, and prognosis: A multiomics perspective.Heart failure reviews · 2025Review
- The Emerging Role of Long Noncoding RNAs in Sorafenib Resistance Within Hepatocellular Carcinoma.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 10 institutions in 6 countries.
Funding
Abstract
backgroundIdentifying novel molecular drivers of disease progression in heart failure (HF) is a high-priority goal that may provide new therapeutic targets to improve patient outcomes. The authors investigated the relationship between plasma proteins and adverse outcomes in HF and their putative causal role using Mendelian randomization. METHODS AND
resultsThe authors measured 4776 plasma proteins among 1964 participants with HF with a reduced left ventricular ejection fraction enrolled in PHFS (Penn Heart Failure Study). Assessed were the observational relationship between plasma proteins and (1) all-cause death or (2) death or HF-related hospital admission (DHFA). The authors replicated nominally significant associations in the Washington University HF registry (N=1080). Proteins significantly associated with outcomes were the subject of 2-sample Mendelian randomization and colocalization analyses. After correction for multiple testing, 243 and 126 proteins were found to be significantly associated with death and DHFA, respectively. These included small ubiquitin-like modifier 2 (standardized hazard ratio [sHR], 1.56;
conclusionsThis study implicates multiple novel proteins in HF and provides preliminary evidence of associations between genetically predicted plasma levels of 17 candidate proteins and the risk for adverse outcomes in human HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.